bearish

CARsgen Therapeutics IPO: Limited Upside as Most Drug Candidates Are in Phase I Studies

301 Views09 Jun 2021 02:19
Our DCF analysis offers limited upside to the company’s indicative IPO price range and our assumptions for the company’s revenue and margin forecasts are not too conservative.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Top Quartile
Shifara Samsudeen, ACMA, CGMA
Equity Analyst
LightStream Research
JapanIndustrialsEquity Bottom-UpEquity Capital Markets
Price Chart(Sign Up to Access)
analytics-chart
x